Zyn-linked colchicines: Controlled-release lipophilic prodrugs with enhanced antitumor efficacy

Journal of Controlled Release

Volumn 40, Issue 1-2, 1996, Pages 89-100

  Baker, Margaret A ^a   Gray, Brian D ^a   Ohlsson Wilhelm, Betsy M ^a   Carpenter, Donald C ^a   Muirhead, Katharine A ^a  

^a Zynaxis Inc   (United States)

Author keywords

Acid hydrolysis; Anticancer activity; Colchicine; Prodrug; Sustained release

Indexed keywords

COLCHICINE; COLCHICINE DERIVATIVE; DRUG VEHICLE; PKH 139; PKH 140; PKH 147; PKH 153; PKH 154; PKH 155; PKH 156; PKH 158; PKH 159; PRODRUG; THIOCOLCHICINE; TUBULIN; UNCLASSIFIED DRUG; ZYN 160; ZYN 162; ZYN 217;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; HUMAN; HUMAN CELL; LIPOPHILICITY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029888584     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00177-8     Document Type: Article

References (31)

1. P.K. Horan, M.J. Melnicoff, B.D. Jensen and S.E. Slezak, Fluorescent cell labeling for in vivo and in vitro cell tracking, Methods Cell Biol. 33 (1990) 469-490.
2. B.D. Jensen, T.C. Schmitt and S.E. Slezak, Labeling of mammalian cells for in vivo tracking by a fluorescence method, Prog. Clin. Biol. Res. 355 (1990) 199-207.
3. S.E. Slezak and P.K. Horan, Fluorescent in vivo tracking of hematopoietic cells. Part I. Technical considerations, Blood 74 (1989) 2171-2177.
4. G.F. Teare, P.K. Horan, S.E. Slezak, C. Smith and J.B. Hay, Long-term tracking of lymphocytes in vivo: the migration of PKH-labeled lymphocytes. Cell Immunol. 134 (1990) 157-170.
5. P.K. Wallace, L.D. Palmer, D. Perry-Lalley, E.S. Bolton, R.B. Alexander, P.K. Horan, J.C. Yang and K.A. Muirhead, Mechanism of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphoctyes and lymphokine-activated killer cells, Cancer Res. 53 (1993) 2358-2367.
6. F.W. Brill, G. A. Kopia, A.R. Olzinski, S. McKenney, T.J. Parry, K. O'Donnell, B.D., Gray, J. Yu, J.F., Burns, K.A., Muirhead, Zynlinkers™, a novel approach to local site-retention and controlled release of pharmaceutical agents, Proc. Int. Symp. Control. Release Bioact. Mater. 21 (1994) 662-663.
7. B.M. Ohlsson-Wilhelm, M.R. McDevitt, B.D. Gray, R. Lorinc, H.B. Mcllvain, K.A. Sheth, S.A. Weeks and K.A. Muirhead, Zyn-Linker delivery of antirheumatic agents, Immunol Res. 13 (1994) 82-95.
8. I.F. Tannock and D. Rotin, Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49 (1989) 4373-4384.
9. A. Roos and W.F. Boron, Intracellular pH, Physiol. Rev. 61 (1981) 296-434.
10. M. Levy, M. Spino and S.E. Read, Colchicine: A state-of-the-art review, Pharmacotherapy 11 (1991) 196-211.
11. E. Hu, R. Ko, R. Koda, P. Rosen, S. Jeffers, M. Scholtz and F. Muggia, Phase I toxicity and pharmacology study of trimethylcolchicinic acid in patients with advanced malignancies, Cancer Chemother. Pharmacol. 26 (1990) 359-364.
12. F.R. Quinn and J.A. Beisler, Quantitative structure-activity relationships of colchicines against P388 leukemia in mice, J. Med. Chem. 24 (1981) 251-256.
13. R.L. Reeves, Condensations leading to double bonds, in: S. Patai (Ed.), The Chemistry of the Carbonyl Group, Interscience Publishers, New York, NY, 1966, pp. 567-619.
14. A. Bruylants and E.F. Medicis, Cleavage of the carbon-nitrogen double bond, in: S. Patai (Ed.), The Chemistry of the Carbon-Nitrogen Double Bond, Interscience Publishers, New York, NY, 1970, pp. 465-504.
15. T. Kaneko, D. Willner, I. Monkovic, J.O. Knipe, G.R. Braslawsky, R.S. Greenfield and D.M. Vyas, New hydrazone derivatives of adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicity, Bioconj. Chem. 2 (1991) 133-141.
16. E. Lavie, D.L. Hirschberg, G. Schreiber, K. Thor, K.E. Hellstrom and I. Hellstrom, Monoclonal antibody L6-daunomycin conjugates constructed to release free drug at the lower pH of tumor tissue, Cancer Immunol. Immunother. 33 (1991) 223-230.
17. B.C. Laguzza, C.L. Nichols, S.L. Briggs, G.J. Cullinan, D.A. Johnson, J.J Starling, A.L. Baker, T.F. Bumol and J.R.F. Corvalan, New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation and representative in vivo activity, J. Med. Chem. 32 (1989) 548-555.
18. L. Velluz and G. Muller, No. 155. The Thiocolchicine, Bull. Soc. Chim. Fr. (1954) 755-757.
19. L. Velluz and G. Muller, No. 224. The Thiocolchicine II -Products of hydrolysis, reduction and oxidation, with example of asymmetric sulfur, Bull. Soc. Chim. Fr. (1954) 1072-1074.
20. G. Muller, A. Blade-Font and R. Bardoneschi, Substitution at C-1 of colchicines, Justus Liebigs Ann. Chem. 622 (1963) 105-113.
21. G.A. Kopia, P.K. Horan, B.D. Gray, D.E. Troutner, K.A. Muirhead, C.-E. Lin, K.A. Sheth, Z. Yu, S.Z. Lever, K.E. Baidoo, B.D. Jensen and S.E. Slezak, Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles, PCT Patent WO93/11120, June 10, 1993.
22. A.K. Godwin, A. Meister, P.J. O'Dwyer, C.S. Huang, T.C. Hamilton and M.E. Anderson, High resistance to cisplatinin human ovarian cancer cell lines is associated with marked increase of glutathione synthesis, Proc. Natl. Acad. Sci. USA 89 (1992) 3070-3074.
23. L.L. Vindelov, I.J. Christensen, N.I. Nissen, A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analyisis, Cytometry 3 (1983) 323-327.
24. E. Fekete and M.A. Ferrigno, Studies on a transplantable teratoma of the mouse, Cancer Res. 12 (1952) 438-442.
25. J.A. Nagy, K.T. Herzberg, J.M. Dvorak and H.F. Dvorak, Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res. 53 (1993) 2631-2643.
26. S.E. Order, V. Donahue and R. Knapp, Immunotherapy of ovarian cancer: an experimental model, Cancer 32 (1973) 573-579.
27. R. Offord and K. Rose, Polypeptide and protein conjugation to proteins, reporter groups and cytotoxic agents for diagnosis and therapy, Eur. Pat. Appl. No. 0243929, April 30, 1986.
28. L.D. Apelgren, D.L. Bailey, S.L. Briggs, R.L. Barton, D. Guttman-Carlisle, G.A. Koppel, C.L. Nichols, W.L. Scott, T.D. Lindstrom, A.L. Baker and T.F. Bumol, Chemoimmumoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs, Bioconj. Chem. 4 (1993) 121-126.
29. E.H. Cordes, Mechanism and catalysis for the hydrolysis of acetals, ketals and orthoesters, Prog. Phys. Org. Chem. 4 (1967) 1-44.
30. R.F. Ozols, K.R. Grotzinger, R.I. Fisher, C.E. Myers and R.C. Young, Kinetic characterization and response to chemotherapy in a transplantable murine ovarian cancer, Cancer Res. 39 (1979) 3202-3208.
31. C.E. Lin, S.P. Duprey, E.B. Jones, S.L. McKenney, B.D. Gray, G.A. Kopia, K.A. Muirhead, Zyn-Linkers as a new delivery agent for oligonucleotides, Proc. Int. Symp. Control. Release Bioact. Mater. 22 (1995) 3210.